|Bid||0.00 x 800|
|Ask||270.00 x 800|
|Day's Range||248.60 - 260.00|
|52 Week Range||118.18 - 280.62|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Jazz (JAZZ) reports data from a mid-stage study on its investigational bispecific antibody targeting HER2-expressing mGEA. The treatment achieved an overall survival rate of 84% in 18 months.
If you are looking for stocks that are well positioned to maintain their recent uptrend, BeiGene, Ltd. (BGNE) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Shares of Chinese pharmaceutical BeiGene (NASDAQ: BGNE) rose as high as 12.8% in early trading on Wednesday. BeiGene didn't make any big announcements, and its earnings report was back on Nov. 9, so the move was curious. Most likely, it was just a little bit of a return to normalcy after the stock took a beating when there were protests in China regarding the country's strict lockdown "zero tolerance" provisions regarding COVID-19.